Clinical Trial Update: Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Novartis-sponsored Phase 2 trial of INC280 (capmatinib) for advanced hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• INC280 (capmatinib) (capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: WITHDRAWN